All In Biotech

NDA 215498 · Ipsen

Bylvay

Odevixibat · Oral · Ileal Bile Acid Transporter Inhibitor

NovelPriority reviewOrphan

CDER novel approval, Jul 20, 2021: To treat pruritus

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jul 20, 2021

Approved uses

3

Original approval plus efficacy supplements

Registered trials

6

6 Phase 3, 0 recruiting

FAERS reports

398

162 serious, 19 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 29, 2025.

BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 12.5 , 14.1 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 ) 1.1 Progressive Familial Intrahepatic Cholestasis (PFIC) BYLVAY is indicated for the treatment of pruritus in patients 3 months of age and older with PFIC. Limitations of Use BYLVAY is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump (BSEP) protein [see Clinical Pharmacology (12.5) and Clinical Studies (14.1) ]. 1.2 Alagille Syndrome (ALGS) BYLVAY is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with ALGS.

Mechanism: Odevixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum . Pruritus is a common symptom in patients with PFIC and ALGS; the pathophysiology of pruritus in patients with PFIC is not completely understood. Although the complete mechanism by which odevixibat improves pruritus in both PFIC and ALGS patients is unknown, it may involve inhibition of the IBAT, which results in decreased reuptake of bile salts, as observed by a decrease in serum bile acids [see Clinical Pharmacology...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 19, 2025 Supplement 5 · Efficacy OrphanLabelLetter
  • Jun 13, 2023 Supplement 3 · Efficacy · priority review OrphanLetterLabel
  • Jul 20, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
4 products under this application
  • BYLVAY · ODEVIXIBAT 1.2MG · CAPSULE, ORAL · Prescription
  • BYLVAY · ODEVIXIBAT 0.4MG · CAPSULE, ORAL · Prescription
  • BYLVAY · ODEVIXIBAT 0.6MG · CAPSULE, PELLETS, ORAL · Prescription
  • BYLVAY · ODEVIXIBAT 0.2MG · CAPSULE, PELLETS, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Odevixibat" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pruritus106
  • diarrhoea99
  • off label use79
  • drug ineffective39
  • liver transplant36
  • product dose omission issue27
  • abdominal pain upper25
  • hepatic enzyme increased25
  • abdominal pain22
  • blood bilirubin increased22
  • alanine aminotransferase increased20
  • bile acids increased20

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20214
202252
202348
202460
2025107
2026127

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bylvay (Odevixibat)

2024 spending

$6.4M

Beneficiaries

n/a

52 claims

Per beneficiary

n/a

$990.50 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,258,158
2023$3,312,672
2024$6,404,368

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7 on PubMed

Sponsor: Ipsen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.